Synthesis and Activity of Functionalizable Derivatives of the Serotonin (5-HT) 5-HT Receptor (5-HTR) Antagonist M100907
Overview
Authors
Affiliations
The approach of tethering together two known receptor ligands, to be used as molecular probes for the study of G protein-coupled receptor (GPCR) systems, has proven to be a valuable approach. Selective ligands that possess functionality that can be used to link to other ligands, are useful in the development of novel antagonists and agonists. Such molecules can also be attached to reporter molecules, such as fluorophores, for the study of GPCR dimerization and its role in signaling. The highly selective serotonin (5-HT) 5-HT receptor (5-HTR) antagonist M100907 (volinanserin) is of clinical interest in the treatment of neurological and mental health disorders. Here, we synthesized the most active (+)-M100907 enantiomer as well as a series of derivatives that possessed either an alkyne or an azide. The triazole resulting from the dipolar cycloaddition of these groups did not interfere with the ability of the bivalent ligand to act as an antagonist. Thus, we have synthesized a number of compounds which will prove useful in elucidating the role of the 5-HTR in the central nervous system.
Bononi G, Lonzi C, Tuccinardi T, Minutolo F, Granchi C Molecules. 2024; 29(9).
PMID: 38731421 PMC: 11085656. DOI: 10.3390/molecules29091930.
Design of bivalent ligands targeting putative GPCR dimers.
Huang B, M St Onge C, Ma H, Zhang Y Drug Discov Today. 2020; 26(1):189-199.
PMID: 33075471 PMC: 7856001. DOI: 10.1016/j.drudis.2020.10.006.
Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.
Anastasio N, Sholler D, Fox R, Stutz S, Merritt C, Bjork J Neuropharmacology. 2020; 168:108009.
PMID: 32145488 PMC: 8980701. DOI: 10.1016/j.neuropharm.2020.108009.
1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.
Bozorov K, Zhao J, Aisa H Bioorg Med Chem. 2019; 27(16):3511-3531.
PMID: 31300317 PMC: 7185471. DOI: 10.1016/j.bmc.2019.07.005.